Pre-clinical study, continued technology development & health economic analysis for Navari Surgical AB

Cancer is one of our times most threatening diseases, killing more than 10 million people each year.

Approximately 60% of all cancer patients will need some type of surgery, where minimal invasive surgery is commonly known as the best type of procedure from the patients perspective, where recovery time and infections can be kept to a minimum.Despite proven benefits from a patient’s perspective, the utilization of minimal invasive cancer surgery remains relatively low.

Limited visualization with large challenges in identifying the cancer tumors position are a strongly contributing factor.

The limited view from the surgical camera makes it challenging for the surgeon to navigate along the surgery procedure, not to mention removing the tumor with precise margins.Navari aims to revolutionize todays minimal invasive cancer surgery, by developing a technology increasing the visualization aspect during this type of procedure.

By utilizing augmented reality, Navari’s innovation can present the surgeon with an AR-projection, showing the cancer tumor and its exact position inside the organ.

The projection of the cancer tumor is shown as an integrated part of the video feed from the surgical camera, enabling live-streamed navigation assistance along the full procedure.

In short terms, our innovation enables surgeons to locate and remove the tumor in the safest and most precise way possible.

In this project, we aim to design and perform a pre-clinical study, realizing our next value enhancing milestone, giving us the validation needed for the innovation to enter future clinical studies.

With the data given from the pre-clinical study, the business model could be validated further, where a health economic analysis could be performed measuring the social sustainability impact of our innovation.

The outcomes from the study, would enable further product optimization from a technical perspective, as well as strengthening our communication towards investors.